Mucopolysaccharidosis Iva
📧 Sign up to get email alerts when something new happens for Mucopolysaccharidosis Iva.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-10-23EMA Authorised: Vimizim (recombinant human n-acetylgalactosamine-6-sulfatase) — BioMarin International Limited
The European Medicines Agency authorised Vimizim for the treatment of Mucopolysaccharidosis IVA (Morquio A) in 2021; Vimizim is an enzyme re…
-
CLINICAL_TRIALS trial_result · 2019-09-26Clinical Trial Update: BMN 110 Phase 3B in Australian Patients [Phase 3]
Phase 3B trial update for BMN 110 in Australian patients with Morquio A syndrome (Mucopolysaccharidosis IVA) has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-06Clinical Trial Update: Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) [Phase 2]
Phase 2 trial of elosulfase alfa (BMN 110) in pediatric patients under 5 with Morquio A syndrome (MPS IVA) has completed and results were po…
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [Phase 3]
Long-term efficacy and safety extension study of BMN 110 in Morquio A syndrome (MPS IVA) completed Phase 3 with results posted.
-
CLINICAL_TRIALS trial_result · 2016-01-12Clinical Trial Update: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation [Phase 2]
Phase 2 efficacy and safety study of BMN 110 (elosulfase alfa) for Morquio A syndrome with limited ambulation was terminated, with results p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-09-30Clinical Trial Update: A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) [Phase 1, Phase 2]
Phase 1/2 study evaluating the long-term efficacy and safety of BMN 110 in patients with Mucopolysaccharidosis IVA (Morquio A) was terminate…
-
CLINICAL_TRIALS other · 2014-04-02Clinical Trial Update: BMN 110 US Expanded Access Program
Expanded access program update for BMN 110 (elosulfase alfa) in Morquio A Syndrome (MPS IVA); status indicates marketing approval.